Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Nov 1;40(41):3409-3417.
doi: 10.1093/eurheartj/ehz203.

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial

Mohapradeep Mohan  1 , Shaween Al-Talabany  1 , Angela McKinnie  2 , Ify R Mordi  1 , Jagdeep S S Singh  1 , Stephen J Gandy  3 , Fatima Baig  1 , Muhammad S Hussain  1 , U Bhalraam  1 , Faisel Khan  1 , Anna-Maria Choy  1 , Shona Matthew  1 , John Graeme Houston  1 , Allan D Struthers  1 , Jacob George  1 , Chim C Lang  1
Affiliations
Randomized Controlled Trial

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial

Mohapradeep Mohan et al. Eur Heart J. .

Abstract

Aim: We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in patients who have coronary artery disease (CAD), with insulin resistance (IR) and/or pre-diabetes.

Methods and results: We randomly assigned 68 patients (mean age 65 ± 8 years) without diabetes who have CAD with IR and/or pre-diabetes to receive either metformin XL (2000 mg daily dose) or placebo for 12 months. Primary endpoint was change in left ventricular mass indexed to height1.7 (LVMI), assessed by magnetic resonance imaging. In the modified intention-to-treat analysis (n = 63), metformin treatment significantly reduced LVMI compared with placebo group (absolute mean difference -1.37 (95% confidence interval: -2.63 to -0.12, P = 0.033). Metformin also significantly reduced other secondary study endpoints such as: LVM (P = 0.032), body weight (P = 0.001), subcutaneous adipose tissue (P = 0.024), office systolic blood pressure (BP, P = 0.022) and concentration of thiobarbituric acid reactive substances, a biomarker for oxidative stress (P = 0.04). The glycated haemoglobin A1C concentration and fasting IR index did not differ between study groups at the end of the study.

Conclusion: Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress. Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials.

Keywords: Oxidative stress; Coronary artery disease; Insulin resistance; Left ventricular mass; Metformin; Pre-diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial consort diagram.
Figure 2
Figure 2
Effect of metformin ton left ventricular mass index and left ventricular mass. (A) This graph illustrates the effect of 12 months of metformin or placebo treatment on the left ventricular mass index. Metformin significantly reduced left ventricular mass index after 12 months of therapy compared with placebo (P = 0.033 for modified intention-to-treat and P = 0.005 for per-protocol analysis). (B) This graph illustrates the effect of 12 months of metformin or placebo treatment on the left ventricular mass. Metformin significantly reduced left ventricular mass after 12 months of therapy compared with placebo (P = 0.032 for modified intention-to-treat and P = 0.005 for per-protocol analysis.
Take home figure
Take home figure
Plausible mechanisms by which metformin regressed left ventricular mass index.
None
See this image and copyright information in PMC

Comment in

References

    1. Ang DS, Pringle SD, Struthers AD.. The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens 2007;20:1029–1035. - PubMed
    1. Aronow WS. Hypertension and left ventricular hypertrophy. Ann Transl Med 2017;5:310.. - PMC - PubMed
    1. East MA, Jollis JG, Nelson CL, Marks D, Peterson ED.. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? J Am Coll Cardiol 2003;41:949–954. - PubMed
    1. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO.. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009;52:153–167. - PubMed
    1. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C.. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895–899. - PubMed

Publication types

MeSH terms